Jean‐Baptiste Micol

Institut Gustave Roussy — France

Medicine · Health Sciences

34h-index5.4kcitations224works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(99), Myeloproliferative Neoplasms: Diagnosis and Treatment(33), Folate and B Vitamins Research(31), Cancer Genomics and Diagnostics(25), Chronic Myeloid Leukemia Treatments(23)

Publications224 total

Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Prospective monitoring of 591 cancer patients with clonal hematopoiesis detected in daily practice
Blood·2025
Mitochondrial dysfunction as a key factor in the predisposition to 14q32-related myeloid hematological malignancies
Blood·2025Open Access
The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy
Blood·2025
Therapy related myeloid neoplasm, same but different?
Bulletin du Cancer·2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer
Annals of Oncology·2025· 4 citedOpen Access
Data from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
2025· 1 citedOpen Access
Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
2025Open Access
Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
2025Open Access
CHIP’ing Signal from Noise in Liquid Biopsy
Clinical Cancer Research·2025· 3 citedOpen Access
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
Blood Cancer Journal·2025· 20 citedOpen Access
Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
Clinical Cancer Research·2025· 8 cited
AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model
Blood·2024· 1 cited
page 1 of 12Next →

Frequent Co-authors

Hervé Dombret(14), Claude Preudhomme(14), Stéphane de Botton(14), Omar Abdel‐Wahab(11), Lionel Adès(9), Céline Berthon(9), Christian Récher(9), Nicolas Duployez(8), Raphaël Itzykson(8), Nicolas Boissel(7), Aline Renneville(7), Christophe Willekens(7), Véronique Saada(7), Christophe Marzac(7), Nathalie Auger(6), Florence Pasquier(6), Pierre Fenaux(6), Arnaud Petit(5), Hélène Lapillonne(5), Karine Celli‐Lebras(5)